Dyadic International (NASDAQ:DYAI) Stock Crosses Above 50 Day Moving Average – Here’s What Happened

Dyadic International Inc. (NASDAQ:DYAI)’s share price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.00 and traded as high as $1.04. Dyadic International shares last traded at $0.9950, with a volume of 235,625 shares.

Analysts Set New Price Targets

DYAI has been the subject of several analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a report on Monday. Craig Hallum initiated coverage on Dyadic International in a research report on Monday, September 8th. They issued a “buy” rating on the stock. Finally, HC Wainwright assumed coverage on Dyadic International in a research report on Thursday, October 23rd. They set a “buy” rating and a $3.00 target price for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $3.00.

Dyadic International Price Performance

The company has a market capitalization of $36.01 million, a PE ratio of -4.15 and a beta of 1.24. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 1.92. The firm’s 50-day moving average is $1.00 and its 200-day moving average is $0.99.

Dyadic International (NASDAQ:DYAI) last released its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The firm had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.22 million. Dyadic International had a negative net margin of 221.09% and a negative return on equity of 537.31%. Equities analysts predict that Dyadic International Inc. will post -0.18 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its stake in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 26,965 shares in the last quarter. Chapin Davis Inc. lifted its stake in Dyadic International by 4.7% in the second quarter. Chapin Davis Inc. now owns 882,849 shares of the biotechnology company’s stock worth $874,000 after purchasing an additional 40,000 shares during the last quarter. AlphaCore Capital LLC purchased a new stake in Dyadic International during the second quarter valued at about $50,000. Perkins Capital Management Inc. boosted its position in Dyadic International by 627.4% during the third quarter. Perkins Capital Management Inc. now owns 348,050 shares of the biotechnology company’s stock valued at $411,000 after buying an additional 300,200 shares during the period. Finally, Truist Financial Corp grew its stake in shares of Dyadic International by 30.5% during the third quarter. Truist Financial Corp now owns 326,200 shares of the biotechnology company’s stock valued at $385,000 after buying an additional 76,200 shares during the last quarter. 27.95% of the stock is owned by hedge funds and other institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.